RCT | Pembrolizumab vs. placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer.

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentaries:

Adjuvant Pembrolizumab in Patients With Completely Resected Stage IB to IIIA NSCLC – The ASCO Post

Adjuvant Pembrolizumab Prolongs DFS in Resected Non-Small Cell Lung Cancer – Cancer Therapy Advisor

Commentary on Twitter

New Research in @TheLancetOncol—Pembrolizumab improves disease-free survival vs placebo in completely resected, PD-L1-unselected, stage IB–IIIA #NSCLC

From Prof Mary O’Brien & colleagues https://t.co/Azqb8WTOwp pic.twitter.com/141bhAPtg5

— The Lancet Respiratory Medicine (@LancetRespirMed) September 13, 2022